MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosisDamiano Rondelli, Robert S. Hoffman, Vikas Gupta et al.|Blood|2014Cited by 153
Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential ThrombocythemiaJohn Mascarenhas, Robert S. Hoffman, Josef T. Prchal et al.|Blood|2016Cited by 28
Safety and Efficacy of Combined Ruxolitinib and Decitabine in Patients with Blast-Phase MPN and Post-MPN AML: Results of a Phase I Study (Myeloproliferative Disorders Research Consortium 109 trial)Raajit K. Rampal, Ronald Hoffman, John Mascarenhas et al.|Blood|2016Cited by 14
Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III TrialRuben A. Mesa, John Mascarenhas, Robert S. Hoffman et al.|Blood|2016Cited by 5
Exploring the Potential of JAK1/2 Inhibitor Ruxolitinib with Reduced Intensity Hematopoietic Cell Transplantation (HCT) for Myelofibrosis: Stage I Results of a Prospective Trial Conducted through the Myeloproliferative Disorders - Research Consortium (MPD-RC)Vikas Gupta, Ronald Hoffman, Heidi Kosiorek et al.|Blood|2016Cited by 2